secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001157523-23-000387
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Aldeyra's NDA for ADX-2191 with Priority Review; PDUFA June 21, 2023
--------------------------------------------------------------------------------

- FDA accepted NDA for ADX-2191 (methotrexate injection) for primary vitreoretinal lymphoma with Priority Review.
- PDUFA date set for June 21, 2023; FDA noted no potential filing review issues identified.
- Planned U.S. launch in second half of 2023, pending FDA approval.
- NDA supported by over 30 years of published literature and safety data from Phase 3 GUARD Trial.
- ADX-2191 has potential to be first FDA-approved drug for primary vitreoretinal lymphoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323000387/0001157523-23-000387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323000387/a53354388.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer